益生菌
布拉迪酵母菌
双歧杆菌
生物
微生物群
人体微生物群
失调
抗菌剂
免疫系统
微生物学
生物技术
乳酸菌
肠道微生物群
微生物毒素
医学
人体研究
生物信息学
抗生素
计算生物学
肠道菌群
放线菌科
免疫学
抗菌肽
人类微生物组计划
抗感染药
作者
Sohn G. Kim,Mericien Venzon,Jonathan P. Jacobs
标识
DOI:10.1146/annurev-physiol-040425-041450
摘要
Probiotics are widely used live microbial supplements intended to promote human health, yet their clinical benefits remain inconsistent and often strain-specific. Most currently available probiotics are derived from Lactobacillus , Bifidobacterium , and Saccharomyces species originally isolated from fermented foods or human microbiota. Preclinical studies suggest that these organisms may influence host physiology through several mechanisms, including antimicrobial activity, toxin inhibition, strengthening of intestinal barrier function, modulation of immune responses, and signaling along the gut–brain axis. However, translation of these mechanisms into consistent clinical benefit has been limited by heterogeneity in probiotic strains, dosing, and study design. Emerging evidence also highlights potential unintended consequences of probiotic use, including rare infections in vulnerable patients, alterations of microbiome recovery after antibiotics, and possible interactions with host metabolism or medications. Recent advances in microbiome research have supported the development of next-generation probiotics and engineered microbial therapeutics, representing a shift toward more targeted and mechanistically informed live microbial therapies.
科研通智能强力驱动
Strongly Powered by AbleSci AI